These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 30640888

  • 21. Catecholaminergic polymorphic ventricular tachycardia.
    Francis J, Sankar V, Nair VK, Priori SG.
    Heart Rhythm; 2005 May; 2(5):550-4. PubMed ID: 15840485
    [Abstract] [Full Text] [Related]

  • 22. Catecholaminergic polymorphic ventricular tachycardia.
    Liu N, Ruan Y, Priori SG.
    Prog Cardiovasc Dis; 2008 May; 51(1):23-30. PubMed ID: 18634915
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Catecholaminergic Polymorphic Ventricular Tachycardia: An Unusual Case of Fright-Induced Prehospital Cardiac Arrest in a Healthy 6-Year-Old Child.
    Wilson M, Schwartz S, Verbeek PR.
    Prehosp Emerg Care; 2020 May; 24(1):94-99. PubMed ID: 31038375
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor.
    Uchinoumi H, Yano M, Suetomi T, Ono M, Xu X, Tateishi H, Oda T, Okuda S, Doi M, Kobayashi S, Yamamoto T, Ikeda Y, Ohkusa T, Ikemoto N, Matsuzaki M.
    Circ Res; 2010 Apr 30; 106(8):1413-24. PubMed ID: 20224043
    [Abstract] [Full Text] [Related]

  • 30. A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.
    Kohli U, Aziz Z, Beaser AD, Nayak HM.
    Pacing Clin Electrophysiol; 2019 Aug 30; 42(8):1146-1154. PubMed ID: 30912151
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations.
    Swan H, Laitinen P, Kontula K, Toivonen L.
    J Cardiovasc Electrophysiol; 2005 Feb 30; 16(2):162-6. PubMed ID: 15720454
    [Abstract] [Full Text] [Related]

  • 36. RYR2 receptor gene mutation associated with catecholaminergic polymorphic ventricular tachycardia in children: a case report & literature review.
    Abdullah NM, Ali A.
    Transl Pediatr; 2024 Feb 29; 13(2):359-369. PubMed ID: 38455755
    [Abstract] [Full Text] [Related]

  • 37. Deadly proposal: a case of catecholaminergic polymorphic ventricular tachycardia.
    Heiner JD, Bullard-Berent JH, Inbar S.
    Pediatr Emerg Care; 2011 Nov 29; 27(11):1065-8. PubMed ID: 22068070
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.
    Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, Klug D, Hayashi M, Takatsuki S, Villain E, Kamblock J, Messali A, Guicheney P, Lunardi J, Leenhardt A.
    Circulation; 2009 May 12; 119(18):2426-34. PubMed ID: 19398665
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.